Details of the Drug Reposition

General Information of This Drug (ID: DMCMBHA)

Drug Name
Erlotinib   DMCMBHA
Synonyms
Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
8 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Salivary gland squamous cell carcinoma DISDI0CT N.A. Approved [1]
Pancreatic adenocarcinoma DISKHX7S N.A. Approved [1]
Esophageal disorder DIS5L3HQ N.A. Approved [1]
Adult hepatocellular carcinoma DIS6ZPAI N.A. Approved [1]
Adrenal gland neoplasm DISFK7RF N.A. Approved [1]
Brain cancer DISBKFB7 2A00 Approved [1]
Lung cancer DISCM4YA 2C25.0 Approved [1]
Psoriasis DIS59VMN EA90 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pancreatic cancer DISJC981 2C10 Phase 3 [2]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Colon cancer DISVC52G 2B90.Z Phase 2 [2]
------------------------------------------------------------------------------------
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple endocrine neoplasia DISZGBKW N.A. Withdrawn [3]
------------------------------------------------------------------------------------
4 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neoplasm of esophagus DISOLKAQ N.A. Discontinued in Phase 2 [4]
HIV infectious disease DISO97HC N.A. Discontinued in Phase 2 [5]
Neuroendocrine neoplasm DISNPLOO N.A. Discontinued in Phase 2 [6]
Squamous cell carcinoma DISQVIFL 2B60-2D01 Discontinued in Phase 2 [7]
------------------------------------------------------------------------------------
2 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neoplastic meningitis DISWWSW7 N.A. Investigative [1]
Neuroblastoma DISVZBI4 2D11.2 Investigative [1]
------------------------------------------------------------------------------------

References

1 Erlotinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
3 Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
4 Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
5 Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism
6 ClinicalTrials.gov (NCT00257699) Study of Antibiotics in the Treatment of Colonic Crohn's Disease
7 Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia